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Abstract
miRNAs  are  sequences  of  20–22  nucleotides  that  participate  in  the  development,
growth,  and  cell  differentiation  by  the  regulation  of  the  mRNAs.Their  possible
participation  in  the  development  of  degenerative  diseases  has  been  extensively
investigated.  Results  show  quantitative  changes  in  miRNA  transcription,  to  the
pathogenesis of various neurodegenerative diseases. In this chapter, the dysregula‐
tion of microRNAs reported in the samples taken from amyotrophic lateral sclerosis
(ALS) animal model or ALS patients is analyzed. Moreover,their probable participa‐
tion in the pathogenesis of the disease is also analyzed.
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1. Introduction
miRNAs are small RNA molecules that do not encode proteins. They are sequences of 20–22
nucleotides that regulate gene expression. miRNAs were identified in 1993 by Lee et al. [1].
Since then numerous studies have been carried out in order to have a better understanding
of their functioning as regulators and, in turn, regulating transcription. These molecules are
transcribed as a longer RNA between 500 and 3000 nucleotides [2, 3]. Then, a serial enzymat‐
ic activity inside the nucleus allows the reduction in the number of nucleotides. These pri-
miRNAs are then exposed to an enzymatic process by using Drosha-associated Pasha (also
known as DGCR8), resulting in a precursor of 65–75 nucleotides in a loop called pre-miR‐
NA, which is transported to the cytoplasm. Finally, the Dicer enzyme breaks for mature single-
stranded fragments comprise 19–25 nucleotides. The last enzymatic activity into cytoplasm
provides an miRNA of 20–22 nucleotides with a complementary sequence of seven base pairs
that enable an miRNA to bind to the target mRNA [3–6].
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The consequence of that complementary interaction could provide the inhibition of translation
or the reduction in the stability of the mRNA resulting in the decrease of the target protein
expression [7]. The importance of these small molecules in gene expression has led to numer‐
ous studies, which aimed at better understanding of its functioning as regulators and, in turn,
the regulation of transcription. Another characteristic is its possibility to target several mRNAs
given a major potential to regulate gene expression or a specific mRNA that can be regulated
by multiple miRNAs [8–10]. Although most authors observed a downregulation by miRNAs,
there are examples of upregulation by miRNAs as well. The ability of a single miRNA to act
both in repression and activation depends on the number of nucleotides that can mate or phase
of the cell cycle in which it is generated [11–16].
In order to homogenize the nomenclature of miRNAs for the pre-miRNA and the pri-miRNA,
they are referred to as uncapitalized “mir,” for the mature form of the miRNA as miR and MIR
for the gene that encodes them [17].
Considering the complexity of the capacity and functions of these small molecules, they have
been linked to several diseases such as cancer [18, 19], autoimmune diseases [20, 21], cardio‐
vascular diseases [22–26], and, of particular interest to our group, are those related to neuro‐
logical diseases.
General reviews on the participation of miRNAs in neurodegenerative diseases have been
emerging, and the research on specific neurological diseases confirms a dysregulation
biogenesis of these small molecules [27–31]. Impaired concentration of blood miRNAs has been
reported in patients with stroke, Alzheimer disease, Huntington disease, Parkinson Disease,
and Amyotrophic Lateral Sclerosis (ALS) [30–46]. In this chapter, ALS disease will be analyzed
in more detail.
The dysregulation of miRNAs in the samples from ALS patients has been reported by several
authors. Until now, it is not clear that which one is the most important dysregulation. This
chapter aims at analyzing those reports that shed light on the enrolled miRNAs and their
participation in ALS pathology.
2. miR-b2403 and miR-b1336 downregulation
During neuron degeneration in ALS diseases, many alterations on neurofilament have been
observed such as the aggregate formation of the perikaryon and proximal axons. In addition,
mRNA of low molecular weight neurofilament (NEFL) decreases [47–49]. A number of reports
agree that an alteration of NEFL synthesis could contribute to the possible cause of neuron
death in ALS patients. Recent reports on the expression analysis of miRNAs, performed on
neurons recovered from sporadic ALS patients’ spinal cord, confirm the downregulation of
miR-b2403 and miR-b1336. These miRNAs modulate NEFL mRNA stability [50]. Consequent‐
ly, it could be the cause of the decreased mRNA, as previously reported in patients with spinal
cord ALS.
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3. miR-338-3 upregulation
The overexpression of miR-338-3 was reported in leucocytes of ALS patients. This miRNA
regulates gene cytochrome c oxidase IV [51]. In vitro experiments report that the transfection
of miR-338 into the axons of primary sympathetic neurons results in a decrease in mitochon‐
drial COXIV mRNAs and consequently a decrease in enzyme protein levels [52]. This protein
belongs to the cytochrome c oxidase complex, the ending step in the mitochondrial electron
transfer chain. Its downregulation results in a decrease in the ATP level and sensitizes the cells
to apoptosis [53, 54]. miR-338 also regulates ATP synthase expression, which is another
mitochondrial enzyme. The postmortem samples from the frontal cortex of patients with ALS
also report on the upregulation of miR-338-3 [55]. The overexpression of miR-338-3 could
induce an axonal respiration functionality and viability damage.
4. miR-29a and miR-29b upregulation
Microarray analysis of miRNAs on samples from three brains of patients with ALS reports the
upregulation of miR-29a. This affects the stability and translation of mRNAs of NAV3, a
nuclear membrane protein-related neuronal regeneration [55]. Unfortunately, there was a
noticeable change in values of the miRNAs for the samples analyzed. In addition, the number
of samples was very small so the analysis does not conclude. However, recently Nolan et al.
[56] have reported an interesting result. The downregulation of the antiapoptotic Mcl-1 was
associated with an upregulation of miR-29a, which enhances the sensitivity of neurons to
endoplasmic reticulum stress-induced apoptosis. In previous research, Nolan et al. found a
high expression for miR-29a in the brain and spinal cord of a family of ALS mouse model. The
intracerebroventricular injection of an miR-29a-specific antagomir does not change disease
manifestation, but the change in the life span was observed [57].
5. miR-9a downregulation
TAR DNA-binding protein 43 (TDP-43) is a nuclear protein related to binding the single-
stranded DNA, RNA, and proteins [58]. In the nucleus, TDP-43 plays a critical role in regulating
RNA splicing as well as modulating microRNA biogenesis. Nevertheless, TDP-43 is a nuclear
factor. A mutant form of the TDP-43 protein can be found in the cytoplasm of affected neuron
in neurological diseases. TDP-43 is considered a major component of the tau-negative and
ubiquitin-positive inclusions in ALS and frontal dementia [59–62]. High levels of TDP-43 are
detected in CSF samples from ALS patients [63]. Recently, it was found that miR-9a expression
significantly reduced on ALS with the TDP43 A90V mutation [64]. It has been proposed that
the genetic interaction studies support the notion that dTDP-43 acts through miR-9a to control
the precision of SOP specification [65]. The in vitro experiment on mice genetic model tissue,
miR-9, demonstrates an upstream regulation of NF mRNAs [66]. In Drosophila TDP43 mutants,
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the miR-9a expression was significantly inhibited [65]. These findings reveal a novel role for
endogenous TDP-43 in neuronal specification and suggest that the functions of the FTD/ALS-
associated RNA-binding protein TDP-43 ensure the robustness of control genetic programs
[65]. Moreover, there is a possibility that TDP-43 may play an important role in miRNA
processing, given an miR-9 downregulation reported on in vitro experiments [64].
6. miR-206 downregulation
Though the main feature is the death of motor neurons, other cells contribute to disease like
muscle cells. In fact, in ALS animal models it was observed that motor neuron death starts
with neuromuscular junction destruction and distal axonal degeneration [67]. The direct
partners of the injured motor axons may respectively be the recipients or initiators of the initial
damage. The bidirectional signaling between motor neurons and skeletal muscle fibers at
neuromuscular synapses has been studied in an animal model. miR-206 is specifically
expressed in skeletal muscle and linked to many disorders in skeletal muscle [68]. The
expression of miR-206 is regulated by myostatin, TGFβ, and IGF [69, 70]. Moreover, the histone
deacetylase 4 and fibroblast growth factor signaling pathways are involved. It was proved that
a response to muscle denervation was activated, which promotes skeletal muscle regeneration
in response to injury [71–74]. In vivo research performed on the ALS model shows the down‐
regulation of miR-206s. This deficiency was correlated with the acceleration of the disease
progression [73]. In patients, miR-206 functions like a key factor for muscle reinnervation and
disease progression [75]. However, sera from ALS patients showed an increase in the circula‐
tion of miR-206 as well as in SOD1-G93A mouse. Samples from biopsies of Biceps brachii
muscle patients with ALS show that miR-206s are overexpressed in the skeletal muscle and
plasma of ALS patients [76, 77]. Nevertheless, this miRNA has no enough data about its relation
with disease status; it has been proposed as a marker [78].
7. miR-146a downregulation
Quantitative PCR performed on ALS spinal motor neuron samples showed dysregulation of
a large number of miRNAs, such as miR-146a and miR-582-3p. An algorithmic program
revealed that these miRNAs are able to interact with NFL mRNA 3´UTR and suggested that
the main role of these miRNAs is to suppress NFL mRNA [79]. Additional reports on miR-146
function dysregulation are related to the inflammation process by inflammatory factors such
as interleukin 1 and tumor necrosis factor-alpha and another process that functions in the
innate immune system by regulating Toll-like receptor signaling [80, 81]. On the other hand,
in vitro experiments performed with mouse neural stem cells showed their relation with
proliferation and differentiation, where miR-146 overexpression promoted spontaneous
differentiation of neural stem cells by downstream Notch 1 gene [82].
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8. miR-524-5p downregulation
Nevertheless, miR-524-5p was inversely associated with the activity of the MAPK/ERK
pathway by suppressing the expression of BRAF and ERK2 proteins on melanoma [83], as a
tumor suppressor in glioblastoma by Jagged-1 and Hes-1 downregulation [84] and in gastric
cancer cells [85]. The results obtained by the application of miRNA recognition element
program, on samples obtained from spinal cord neurons of sporadic ALS patients, showed
that this miRNA is able to directly regulate the NFL by downregulating its synthesis in neuron
cells. However, in ALS patients, it is decreasing and by consequence there is an overproduction
of NFL which is a deleterious effect. On the other hand, the overexpression of miR-524-5p
inhibits the MAPK/ERK pathway; apparently these cells could demonstrate a high activity on
the MAPK/ERK pathway and cytoplasm NS accumulation.
9. miR-124 downregulation
miR-124 has been found to be the most abundant microRNA expressed in neuronal cells. Its
targets are laminin γ1 and integrin β1. Nevertheless, experiments to alter expression of
miR-124 in neural cells did not appear to affect differentiation [86]. However, later research
reports described the role of miR-124 during neuronal differentiation by the overexpression
of miR-9* and miR-124 in neural progenitors [87]. In a recent work, it was demonstrated that
exosomes containing miR-124a releasing from neurons that can be directly internalized into
astrocytes, with a concomitant increase in miR-124a, induce an increase in the levels of GLT1
protein [88]. miR-124a was found downregulated in the spinal cord of mutant SOD1 mouse
models. In vivo injection of miR-124a into oligonucleotides in the spinal cord of ALS mice
significantly prevents further pathological loss of GLT1 protein.
10. Other dysregulate miR
De Felice et al. [51] analyzed 911 mRNA expression by microarray in leukocytes of 14 patients
with sporadic ALS. In addition to miR-338-3p, they identified eight miRNAs with changes in
expression, e.g., hsa-miR-451, hsa-miR-1275, hsa-miR-328, hsamiR-638, has-miR-149, and the
expression decreased for miR583 and miR-665 [51]. Campos-Melo et al. [79] also reported a
decrease in most miRNAs, such as miR-146a, miR-524-5, and miR-582-3, from neurons of the
spinal cord in the lower back. In addition, miR-b2403 and miR-b1336 are underregulated in
the spinal cord samples; both are related to the stabilization of mRNA NEFL as well as
miR-338-3 as previously reported [50, 51]. The consequence of the accumulation effects on the
NEFL mRNA could be the cause for the decrease in mRNA previously reported in patients
with spinal cord ELA [47]. Reports of miRNAs expression analysis performed on the samples
of neurons recovered from the brain or spinal cord of ALS patients have been able to confirm
a reduction in miRNAs that modulate gene NEFL stability (for the synthesis of light neurofi‐
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lament), the cytochrome c oxidase gene, and protein of the nuclear membrane NAV3 and
related neuronal regeneration.
Other cells that contribute to the disease are microglia cells, lymphocytes, and Schwann cells
[89–91]. A recent hypothesis is that Schwann and muscle cells are also direct partners of the
injured motor axons and may respectively be the recipients or initiators of the initial damage
[67, 92].
In a mice ALS model, it has been proved that miR-365 and miR-125b suppress the IL-6/STAT3
pathway in microglia cells with an increase in the levels of TNFα mRNA [93]. This agrees with
the fact that TNFα is upregulated in G93A mice and ALS patients [94, 95], which indicates that
miR-365 and miR-125b dysregulations might develop the pathological cytokine profile on ALS.
11. Conclusion
Until now, there is no consensus on which miRNA could be the best target for therapy. To alter
the cell homeostasis of miRNAs, more than one change is needed for their biogenesis. Similar
to previous reports, miRNA can have several target mRNAs and one mRNA can be regulated
by different microRNAs. ALS research provides an example of NEFL synthesis alteration,
which can be regulated by miR-b2403, miR-b1336, miR-146a, miR-524-5p, and miR-582-3p.
Probably, for the development of diseases, the coincidence of more than one dysregulation is
necessary, or the accumulative alteration of various changes in the transcriptome, to induce
neuron cell death. On the other hand, the dysregulation of miRNAs on neighbor cells partic‐
ipates in ALS pathology, where microglia cells, lymphocytes, Schwann cells, and muscle cells
show a dysregulation in the miRNA transcript. Further, miRNAs also participate in neuron
death. Nevertheless, research on miRNAs involves looking at miRNAs from the perspective
of biomarkers. Moreover, the systematic comparative analysis of their profile between healthy
people and ALS patients provides information on which pathways can be suggested as
possible targets for directed therapy. In addition, the analysis also provides an opportunity to
know more about the development of this disease, metabolic pathways altered, and cells
involved in ALS pathology.
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